Sudeep Pharma Limited share price
NSE: SUDEEPPHRM · ISIN INE0QPI01025
Key numbers
- Market cap
- ₹ 13,157 Cr
- Current price
- ₹ 1,164.90
- 52-week high / low
- ₹ 1,378 / 524
- Stock P/E
- 72.3
- Book value
- ₹ 78.2
- Dividend yield
- 0.13%
- ROCE
- 28.1%
- ROE
- 25.1%
- Debt to equity
- 0.17
- Sales growth (3 yrs)
- 14.4%
- Profit growth (3 yrs)
- 40.5%
- 1-year return
- -
About Sudeep Pharma Limited
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy products. In addition, the company provides a range of mineral powders and granules for carbonated, non-carbonated, and nutraceutical beverages; tricalcium phosphate, dicalcium phophate, dipotassium phosphate, ferric pyrophosphate, and disodium phosphate. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 158 | 125 | 172 | 182 | 158 |
| Operating profit | 59 | 44 | 60 | 63 | 55 |
| Net profit | 44 | 31 | 47 | 49 | 41 |
| EPS (₹) | - | 2.73 | 4.29 | - | 3.59 |
Concall summary (2026-08-11)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- We are confident that his guidance and insight will further strengthen our leadership team and support the company as we enter the next phase of our growth journey.
- As these conditions gradually normalize, we believe our international business remains well-positioned to continue growing while contributing positively to our overall margin profile and supporting our target to sustain EBITDA margins between 37% and 38%.
Growth & demand
- We delivered revenue growth of 27% year-on-year, driven by broad-based performance across both our pharma, food and nutrition and specialty ingredient business.
- Our specialty ingredients business delivered 19% year-on-year growth during the quarter.
Margins & costs
- Continued logistics disruptions, elevated freight costs, and a sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter.
- Despite these headwinds, we remained focused on protecting customer relationships, ensuring continuity of supply, and effectively passing on the price increase, which will largely offset the input cost impact in Q2.
Capex & expansion
- So, I would say the growth in PFN today from our current capacity which is probably with a maybe couple of percent is what we can extract further in terms of sweating the asset, but beyond that, we will have to wait for the greenfield to be commissioned in Q3 to kind of to kind of have that additional alpha in growth.
- So that is, let's say, 50% or basically a large part of the capacity is actually going into expansion of our existing capacity, which is the phosphate product, and then bringing newer products to market, which is the bisglycinate, the gluconate, the citrate products from the new site.
Balance sheet & cash
- These efforts have helped us mitigate cost pressures, improve operational leverage and support our overall business performance during the quarter.
- PAT margin improved to 25.6% from 25%, reflecting enhanced operating leverage and efficient capital management.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.